Bastion Therapeutics is focused on developing engineered regulatory T cell (Treg) therapies aimed at restoring balance in the immune system to treat inflammatory disorders. Their proprietary GRIT™ Platform leverages the multi-functional capabilities of Tregs, which are specialized white blood cells that play a crucial role in modulating immune responses and reducing inflammation. By enhancing Treg activity, the company aims to address the underlying causes of various inflammatory conditions, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and asthma. This approach seeks to counteract the dysregulation of the immune system that leads to chronic inflammation, thereby transforming the treatment landscape for patients suffering from these disorders.

The therapeutic potential of Tregs extends beyond merely suppressing immune responses; they also contribute to tissue repair and regeneration. Bastion Therapeutics is committed to advancing its pipeline of Treg-based therapies, which are designed to provide comprehensive treatment solutions by addressing the complex nature of inflammatory disorders. Through ongoing research and development, the company aims to unlock the full spectrum of Treg capabilities, ultimately striving to create curative therapies that can significantly improve patient outcomes and quality of life.

United Kingdom

Bastion Therapeutics is a preclinical stage biotechnology company with a mission to develop novel Treg therapies to address the unmet clinical need for inflammatory disorders.

We leverage our proprietary GRIT™ platform technology to enhance Tregs to modulate the immune system and overcome challenges associated with previous generations of Treg therapies.

Our vision is to provide life-changing therapies that are efficacious, durable and safe to patients suffering from inflammatory disorders.

Bastion Therapeutics

Company Details